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A combination of psoralens and ultraviolet A radi-
ation is widely used to treat psoriasis. Long-term,
high-dose exposure to psoralen + ultraviolet A is
associated with an increased risk of nonmelanoma
skin cancer, particularly squamous cell carcinoma. In
this study, we used p53 mutations as a molecular
marker to determine the separate contributions of
psoralen + ultraviolet A and other ultraviolet expos-
ures, such as ultraviolet B for skin cancer develop-
ment in psoralen + ultraviolet A-treated psoriasis
patients. The results indicated that of 69 tumors ana-
lyzed, 37 (54%) tumors had one or more p53 muta-
tions. Of 37 tumors with mutations, 17 (46%)
tumors had only ultraviolet-type mutations, two
(5%) tumors had only psoralen + ultraviolet A-type
mutations, and 18 (49%) tumors had both types of
mutations. Interestingly, psoralen + ultraviolet A-
type p53 mutations were more frequent than ultra-
violet type in tumors arising in patients with high-
dose exposure to psoralen + ultraviolet A. Field
cancerization and tumor heterogeneity appeared to
occur frequently in the same patient and even in the
same tumor. This study's data suggest that psora-
len + ultraviolet A-induced p53 mutations may play
an important part in the development of nonmela-
noma skin cancer in psoralen + ultraviolet A-treated
patients, but these mutations are likely to act in con-
cert with the effects of other carcinogenic exposures,
particularly ultraviolet B, in the development of skin
cancer. Key words: psoriasis/skin neoplasms/tumor sup-
pressor gene. J Invest Dermatol 119:522±526, 2002
I
n 1974, photochemotherapy for psoriasis utilizing oral 8-
methoxypsoralen and ultraviolet A (PUVA) was introduced
for the treatment of psoriasis (Parrish et al, 1974; Haber,
1974). PUVA is highly effective and widely used in treating
psoriasis, vitiligo, cutaneous T cell lymphoma, and other
skin disorders. In PUVA-treated patients, a concentration-depen-
dent increase in both the risk of squamous cell carcinoma (SCC)
and, with very long-term treatment melanoma has been demon-
strated (Stern et al, 1984, 1997, 1998). The risk of SCC is most
elevated in patients with high-dose exposure to PUVA, particularly
those with exposure to at least 200 PUVA treatments (Stern et al,
1998). The increased risk of SCC may be a consequence of a
multitude of effects following PUVA treatment, direct as well as
indirect. In addition to its mutagenic and carcinogenic effects,
PUVA is immunosuppressive (Kripke et al, 1983; Morison and
Kripke, 1984). Long-term immunosuppressive therapy is a
substantial risk for SCC (LindeloÈf et al, 2000). In addition, PUVA
in¯uences cellular functions and release of cytokines, which
might have an impact on the progression of skin cancer (Tokura
et al, 1999).
Psoriasis patients exposed to high doses of PUVA therapy are also
likely to have had substantial exposure to natural sunlight, UVB
phototherapy, topical corticosteroids, and a variety of systemic
therapies, including oral retinoids and methotrexate. These expos-
ures might act independently or as cocarcinogens with PUVA
(Stern and Laird, 1994; Stern et al, 1998). More recently,
immunosuppressive therapies for psoriasis, which are likely to
substantially impact on the risk of SCC, have been introduced
(Stern, 1989); however, these therapies were not in widespread use
within our study cohort.
PUVA is a potent mutagen and carcinogen (Pathak et al, 1959;
Ananthaswamy, 1985; Sage and Bredberg, 1991; Sage et al, 1993;
Nataraj et al, 1996; Gasparro et al, 1998). In experimental systems, it
induces characteristic mutations in p53 and other genes that are
quite different from those induced by UVB (Sage and Bredberg,
1991; Sage et al, 1993; Nataraj et al, 1996, 1997; Peritz and
Gasparro, 1999). This could be attributed to the fact that PUVA
induces different types of DNA damage than UVB. Whereas
PUVA induces monofunctional adducts and DNA cross-links
(Ben-Hur and Elkind, 1973; Song and Tapley, 1979; Sage, 1993;
Gunther et al, 1995; Gasparro et al, 1998), UVB induces mainly
cyclobutane-type pyrimidine dimers and (6±4) photoproducts
(Rosenstein and Mitchell, 1987). In addition to these photo-
products induced by the direct action of PUVA and UVB on
cellular DNA, other oxidative lesions such as 8-oxo-2¢-deoxygua-
nosine (8-oxodG) are also induced indirectly by UVB and PUVA
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via reactive intermediates (Rosen et al, 1996; Zhang et al, 1997; Liu
et al, 1999; Cooke et al, 2001). It is interesting to note that both
pyrimidine dimers and 8-oxodG are induced and excreted in the
urine of human volunteers exposed to suberythemal doses of UVA
lamps used in PUVA therapy (Cooke et al, 2001); this implies that
8-oxodG may play a part in the development of SCC in PUVA-
treated patients. In fact, 8-oxodG has been shown to be mutagenic
(Kuchino et al, 1987). Although multiple mechanisms may
contribute to the occurrence of nonmelanoma skin cancer
(NMSC) in PUVA-treated patients, an in-depth analysis of p53
mutations in tumors arising in PUVA-treated patients could help
clarify the relative contribution of the mutagenic and carcinogenic
effects of PUVA and UVB.
The p53 suppressor gene is a major target for carcinogen-speci®c
mutations. Human skin cancers arising in the general population
(non-PUVA-treated patients) as well as UV-induced mouse skin
cancers exhibit a high frequency of UV signature (C to T and CC
to TT) mutations (reviewed in Nataraj et al, 1995; Brash et al,
1996). In contrast, PUVA-induced mouse skin cancers contain p53
mutations at 5¢-TpA/ApT or 5¢-TpT sequences that are quite
distinct from those found in UV-induced skin cancers (Nataraj et al,
1996). In addition, previous studies have shown that SCC arising in
PUVA-treated psoriasis patients from Austria, contained both UVB
and PUVA signature mutations (Nataraj et al, 1997); however,
Wang et al (1997) found that tumors arising in PUVA-treated
patients from the United States had only the UVB type of
mutations. Similarly, Seidl et al (2001) recently demonstrated that
basal cell carcinomas (BCC) arising in PUVA-treated psoriasis
patients contained mostly UV-type mutations in the p53 gene. The
reason for this discrepancy could be attributed to the fact that we
may have overestimated the frequency of PUVA-type mutations in
our study because we considered some C to T mutations at
nondipyrimidine sites as PUVA type. As C to T mutations at
nondipyrimidine sites are also found in skin cancers arising in the
general population, they cannot be considered as PUVA type.
Therefore, additional studies using a large sample size and patient
population are needed to determine if PUVA contributes to the
increased incidence of SCC by exerting its mutagenic and
carcinogenic effects directly on target genes and cells. We therefore
analyzed a total of 113 specimens from 69 tumors collected from 29
PUVA-treated patients for the presence of PUVA and UVB
signature mutations in the p53 gene. In addition, we determined
the extent of heterogeneity in p53 mutations both within the same
tumor and in separate tumors that arose in the same patient. If
speci®c mutations in the p53 gene are present in tumors arising in
PUVA-treated patients, we can hypothesize that the mutagenic
effects of PUVA and/or UVB played a part in the etiology of those
tumors (Nataraj et al, 1997; Gasparro et al, 1998).
MATERIALS AND METHODS
The PUVA Follow-up Study was organized in 1975 and includes many
of the ®rst patients with psoriasis to be treated with oral photochemo-
therapy (Stern et al, 1979). The study has prospectively followed for
nearly 25 years in 1380 patients ®rst treated with PUVA in 1975 or
1976. As of 1998, there were approximately 900 surviving patients.
From 1975 to July 1998, we had documented 2693 BCC or SCC
among 384 of the 1380 originally enrolled patients. The observed
increase in risk of SCC among cohort members was dose related.
Compared with the increase in risk associated with PUVA use, other
exposures, including UVB phototherapy, methotrexate, and topical tar
were, at most, modest risk factors for the development of SCC and BCC
in this cohort (Stern and Laird, 1994). The PUVA Follow-up Study
submitted 113 separate specimens from SCC and BCC for mutational
analysis to the laboratory of Dr Ananthaswamy. All specimens were
submitted without any information concerning patient or tumor charac-
teristics to prevent any bias before the ®nal analysis. The patients
incurred no additional risks as a result of this study, which was conducted
with the approval of The University of Texas M.D. Anderson Cancer
Center Institutional Review Board.
DNA extraction Two methods were used to extract DNA from
paraf®n-embedded sections. The ®rst was the sonication method (Heller
et al, 1991), with minor modi®cations. Five to 10 mM sections were
deparaf®nized with xylene, suspended in 100±200 ml of lysis buffer
(40 nM KCl mM Tris, pH 8.3, 1.5 mM MgCl2, 0.01% gelatin, 0.5%
Tween 20, and 0.5 mg proteinase K per ml), and sonicated with sterile
glass beads (Sigma, St Louis, MO) at 55°C for 30 min using a Branson
Model 2200 (Branson Ultrasonic, Danbury, CT). The samples were then
boiled for 15 min and spun for 1 min. The resulting supernatant was
stored at ±20°C until used. In the second method, after deparaf®nizing,
samples were washed two times with 100% and 70% ethanol, dried in a
heating block, and suspended in Release-IT reagent (CPG, Inc., Lincoln
Park, NJ). The tissues were grounded using disposable pestles and lyzed
directly in ampli®cation tubes in a thermal cycler, according to the
manufacturer's instructions. Lysed samples were stored at ±20°C. Each
sample was screened for p53 mutations by both methods.
Polymerase chain reaction±single strand conformation
polymorphism (PCR±SSCP) analysis Exons 4±9 of the p53 gene
were ampli®ed separately using speci®c upstream and downstream
primers encompassing intron±exon junctions. All primers were custom
synthesized by Genosys Technologies, Inc. (The Woodlands, TX). Five
microliters of the lysates were used as templates in a 50 ml solution
containing 10 mM Tris±HCl (pH 8.3); 50 mM KCl; 1.5 mM MgCl2;
0.001% gelatin; 150 ml each of deoxyadenosine triphosphate,
deoxyguanosine triphosphate, deoxycytidine triphosphate, and
deoxythymidine triphosphate; 2.5 mCi of [a-32P]deoxycytidine
triphosphate; upstream and downstream primers (10 mM each); and 5 U
AmpliTaq (Perkin Elmer, Foster City, CA). The reaction mixture was
overlaid with mineral oil (Sigma, St Louis, MO) and PCR was carried
out in a DNA thermal cycler (Perkin Elmer) as follows. The DNA was
denatured at 94°C for 4 min followed by two cycles at 94°C (1 min),
65°C (1 min), and 72°C (1 min); ®ve cycles at 94°C (1 min), 60°C for
15 min to complete the extension. An aliquot (3 ml) of the PCR
product was subjected to SSCP analysis on 5% Mutation Detection
Enhancement (FMC Bioproducts, Rockland, ME) acrylamide gels with
10% glycerol, as described previously (Kanjilal et al, 1993). The gel was
run at 6 W for 14±18 h, dried and exposed to autoradiographic ®lm.
Extreme precaution was taken to avoid contamination, and blank PCR
controls without DNA templates were included in every PCR reaction.
In addition, human placental DNA was included in every PCR reaction
as a normal control. PCR±SSCP analysis was performed three times for
each sample.
Nucleotide sequencing Wild-type and shifted (mutant) bands were
cut out of the dried SSCP gels, and the DNA was eluted by incubating
at 80°C for 30 min in 100 ml of Tris-EDT buffer. The eluted DNA was
reampli®ed by PCR using the same primers and conditions described
above and the PCR products were analyzed on 2% agarose gel along
with a Low Mass DNA ladder (Life Technologies, Gaithersburg, MD) to
verify successful ampli®cation and quantify the products for further
sequencing analysis. The samples were treated with shrimp alkaline
phosphatase and exonuclease I (USB, Cleveland, OH) for 15 min at
37°C and 15 min at 80°C before direct sequencing using the Thermo
Sequenase radiolabeled terminator cycle sequencing kit (USB). In some
cases genomic DNA from SSCP-positive tumors was ampli®ed by cold
PCR and the products sequenced directly to con®rm the mutation. In
addition, to rule out PCR-generated mutations, human placental DNA
was simultaneously ampli®ed and sequenced in every experiment.
RESULTS
In this study, we examined NMSC arising in psoriasis patients who
had long-term exposure to PUVA before the removal of the ®rst
tumor. All p53 mutation analyses were performed with the
laboratory blinded as to the type of tumor and whether the
specimen was the only one or one of multiple specimens from a
tumor. Tumor tissues were ®rst screened by SSCP analysis for p53
mutations in exons 4±9, because over 95% of all mutations are
known to occur at these exons in human cancers (Greenblatt et al,
1994). Tumors harboring p53 mutations were identi®ed by the
presence of aberrant (shifted) bands by SSCP. DNA from these
bands was then eluted, reampli®ed, and sequenced to determine the
nature of mutations.
The 69 tumors analyzed as 113 separate specimens came from 21
patients, of whom 15 (71%) had at least one tumor with a p53
mutation. The characteristics of the 21 patients studied are
summarized in Table I. The anatomic distribution of tumors
used in this study is shown in Table II. Of the 69 NMSC analyzed
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for p53 mutations, 51 were SCC (74%), including one initially
diagnosed as a SCC and subsequently diagnosed as hypertrophic
actinic keratosis, which is included as a SCC in our analysis. The
remaining 18 tumors were BCC. A higher percentage (61%) of
SCC harbored p53 mutations compared with BCC (33%) (p<0.05,
chi square test). Overall, 86% of SCC with two or more separate
slides or blocks analyzed had a p53 mutation and 67% of such
tumors had a PUVA-type mutation. BCC were signi®cantly more
likely to come from the head and neck than SCC (Table II). Some
tumors had multiple independent specimens (blocks or histologic
slides) analyzed. Therefore, a given tumor might have all PUVA-
type mutations, all UVB-type mutations, mutations of both types,
or no mutations.
We detected a total of 83 p53 mutations in 55 (49%) of 113
specimens. Of the 15 patients with PUVA-type or UVB-type
mutations detected in one or more specimens, one patient (6.7%)
had tumors with only PUVA mutations, six patients (40%) had
tumors with only a UVB-type mutation, seven patients (46.6%) had
both UVB and PUVA-type mutations in their tumors, and one
patient (6.7%) had a tumor with mutations classi®ed as ``other'' type
(Fig 1A). All but one patient (91%) with more than one tumor
analyzed had at least one mutation. Of the 83 mutations, C to T
and CC to TT transitions represented 27% and 16%, respectively,
and T to A and TT to AA transversions represented 11 and 8.0%,
respectively (Fig 1B). Interestingly, T to C transitions occurred at a
relatively high percentage (31%). Mutations occurring at 5¢-TpA/
ApT and 5¢-TpT sites, potential sites for PUVA-induced mono-
adducts and DNA cross-links, were considered to have been
induced by PUVA, and C to T, CC to TT and T to C transitions at
CC, CT, and TC sites were considered to have been induced by
UV; however, it is quite possible that C to T transitions may also
arise from indirect effects of PUVA. It is well known PUVA and
UVA radiation causes DNA damage indirectly and produce
reactive oxygen intermediates and oxidative lesions such as 8-
oxodG (Rosen et al, 1996; Zhang et al, 1997; Liu et al, 1999; Cooke
et al, 2001), which is reported to be mutagenic (Kuchino et al,
1987). In addition, Reid and Loeb (1993) demonstrated that
reactive oxygen species such as hydroxyl radicals can induce C to T
and CC to TT transitions, and Wang et al, 1988) showed that stable
oxidation products of cytosine and thymine can induce C to T
transitions. Thus, it is reasonable to speculate that some of the
mutations found in skin cancers from PUVA-treated psoriasis
patients could have been induced by the indirect action of PUVA
or UVA (Peritz and Gasparro, 1999); however, our understanding
of PUVA-induced photochemistry in vivo human cells is far from
complete. Nonetheless the presence of mutations at these sites
suggest that these sequences are potential hot spots for PUVA- or
UV-induced mutations in psoriasis patients who have undergone
PUVA treatment. CC to TT and C to T transitions at dipyrimidine
sites occurred at codons 157±158, 247±248, and 250, which are
also hotspots in NMSC from non-PUVA-treated patients (Brash et
al, 1996). The p53 mutation data summarized in Table III reveal
that 34 of 83 mutations were characteristic of PUVA-induced
mutations (41%), 36 mutations (44%) had the UV signature, and 13
were categorized as ``other'' type (15%), meaning they could have
been induced by UV or PUVA, or they arose spontaneously during
tumor progression.
Twenty-four (44%) of 55 specimens had multiple UVB and/or
PUVA-type p53 mutations. Even though some tumors from the
same patient had both PUVA-type and UV-type mutations, one
type occurred more frequently than the other. For example, tumor
4 from patient 1 had a total of six mutations in four specimens, of
which ®ve were PUVA type and one was UV type. Similarly,
tumor 3 from patient 2 had a total of 13 mutations in six specimens,
of which 10 were PUVA type, two were UV type and one other
type. Conversely, tumor 2 from patient 9 had a total of six
mutations in four specimens, of which ®ve were UV type and one
was PUVA type. These results suggest that more likely PUVA was
the primary carcinogen in tumors 4 and 3 from patients 1 and 2,
respectively, and UV was the primary carcinogen in tumor 2 from
patient 9. When the characteristics of tumors that had a mutation
were compared with those without mutation there were two major
differences. The likelihood a tumor would have a mutation
increased with the number of separate specimens analyzed from that
tumor. For tumors with at least two separate specimens analyzed,
82% had mutation(s) compared with only 46% of tumors with only
a single specimen analyzed (p < 0.01, chi square test). In fact, there
was a signi®cant association between the number of separate
specimens examined and the likelihood of having a PUVA and/or
UVB p53-type mutation (ANOVA, p = 0.05).
The age of patients whose tumors displayed at least one tumor
with only PUVA-type mutations tended toward being younger
than those whose tumors had only a UVB-type mutation,
mutations of both types, or no mutation, but this did not reach
statistical signi®cance. Tumors that had only UVB mutations
occurred after fewer PUVA treatments than tumors that displayed
PUVA-type mutations, but this did not reach statistical signi®cance.
DISCUSSION
We used p53 mutations as a molecular marker to determine
whether PUVA or UVB is associated with the induction of skin
tumors in PUVA-treated psoriasis patients. This study demonstrates
that in a U.S. population of patients treated with PUVA, 41% of all
p53 mutations detected were characteristic of those associated with
PUVA exposure. Nearly three-fourths of SCC that developed after
exposure to at least 300 PUVA treatments exhibited mutations of
the type associated with PUVA. In addition to PUVA-type
mutations, UV-type mutations were also present at a high
frequency (44%) in NMSC arising in PUVA-treated patients.
There was a trend for patients with only UVB-type mutations to
more often be fair-skinned and burn easily and be older, but not to
have more exposure to UVB for psoriasis therapy. These ®ndings
suggest that exposure to natural sunlight rather than therapeutic
UVB play a greater part in inducing UVB-type mutations. The
Table I. Characteristics of 21 patients included in this
studya
Patient history/characteristics Mean Range SD
Male 10; female 11
Age at ®rst tumor analyzed 60 (42±77) 12
PUVA treatment to ®rst tumor analyzed 329 (93±613) 178
Number of tumors analyzed 3.3 (1±4) 2.8
Years of methotrexate use to last tumor 5.5 years (0±20) 4.8
(17 of 21 had used methotrexate)
Number of SCC (up to last tumor) 17 (1±93) 25
Number of BCC (up to last tumor) 6 (0±28) 9
Years from ®rst PUVA to ®rst tumor analyzed 14.0 (3±18) 4
aSkin type (one patient was not skin typed): 1 = 1 patient, 2 = 9 patients, 3 = 9
patients, 4 = 1 patient; history of exposure to ionizing radiation for psoriasis = 2
patients (10%); high exposure to UVB/tar = 4 patients (33%).
Table II. Anatomic location by tumor and tumor type
Site
Tumor type
SCC BCC All
Face/neck 3 11 14
Upper extremities 8 8
Trunka 7 4 11
Lower extremities 33 3 36
Total 51 18 69
aIncludes anogenital tumor.
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presence of UVB signature p53 mutations is expected because the
UVA lamp source used in PUVA therapy invariably contains some
UVB radiation. In addition, some of the patients may also be
exposed to prior UVB phototherapy or natural sunlight post-
PUVA therapy. Nonetheless, these results are somewhat different
from a previous ®nding that about 64% of p53 mutations detected
in NMSC from PUVA-treated psoriasis patients from Austria were
of PUVA type and about 32% were of UVB type (Nataraj et al,
1997). This discrepancy is attributed to the fact that we considered
some mutations occurring at dipyrimidine sites such as 5¢-CpT sites
as PUVA type. In fact such mutations are also present in UV-
induced skin tumors and hence cannot be considered as PUVA
type. Nonetheless, Wang et al (1997) reported that the frequency of
UVB-type mutations in SCC developing in PUVA-treated patients
was comparable with that of tumors arising in non-PUVA-treated
patients; however, they did not detect PUVA-type mutations in
any of the tumors from PUVA-treated patients. Similarly, a recent
study by Seidl et al (2001) has shown that BCC from PUVA-treated
Austrian patients contained mostly UV-type p53 mutations. The
reason for the discrepancy between these studies and our study is
unknown but could be attributed to differences in dose and extent
of PUVA treatment, genotypic and phenotypic characteristics of
patients, or other unknown factors. Alternatively, the differences in
patient population could also account for this apparent discrepancy.
In about half of the specimens analyzed we failed to detect a p53
mutation characteristic of those associated with PUVA or UVB.
The reasons for this might include the following:
1 We analyzed only exons 4±9 of p53 gene because over 95% of all
mutations are known to occur at these exons in human cancers
(Greenblatt et al, 1994). It is possible that mutations could also
occur in exons 1±3 and 10 and 11 in skin cancers from PUVA-
treated patients; however, we did not look for mutations at these
exons.
2 Some specimens contained silent mutations. We did not count
them as mutation-positive because those mutations did not change
the corresponding amino acid.
3 Some of the samples may contain large amounts of normal cell
contamination, which can mask detection of mutations by the
direct sequencing technique used, particularly if only one p53 allele
is mutated in tumor cells.
4 A higher proportion of tumors without mutations detected were
BCC, which are less strongly associated with sunlight than SCC.
Nonetheless, when multiple specimens from the same tumor
were analyzed, a p53 mutation was more likely to be detected and
multiple mutations were often present. Even within single
specimens, multiple mutations characteristic of both UVB and
PUVA exposure, were detected in about one-seventh of speci-
mens. Interestingly, however, a given tumor from a patient with
multiple tumors, even though it had both PUVA- and UV-type
mutations, one type (either PUVA or UV) of mutation often
dominated over the other, which suggests that the dominating
component presumably came ®rst, creating the founder mutant
cell, and one of the progeny cells acquired mutations later by the
second carcinogen. Thus in tumors 4 and 3 from patients 1 and 2,
respectively, PUVA could be the major carcinogen and UV the
minor component. Conversely, in tumor 2 from patient 9, UV
could be the major component and PUVA the minor component.
As neither type of mutation was present in every sample of a tumor,
p53 mutation may not have been the ®rst event in tumorigenesis
and may not have conferred a growth advantage.
The presence of multiple p53 mutations has also been reported in
human and UV-induced mouse skin cancers and head and neck
cancers (Kanjilal et al, 1993; Lydiatt et al, 1998). The presence of
multiple mutations in the same tumor is consistent with our earlier
observation that suggest ®eld cancerization (Kanjilal et al, 1995).
Field cancerization is postulated to result from prolonged exposure
to carcinogens. Numerous mutations accrue throughout the ®eld
or area sharing the carcinogen exposure(s), and some of the
initiated cells progress to multiple primary tumors. The presence of
multiple p53 mutations observed in PUVA-induced mouse skin
cancers suggests (i) that clones harboring an initial mutation on one
Table III. Frequency of PUVA and UV type p53 mutations
in skin cancers from PUVA-treated patients
Mutation typea
Number of speci®c mutations/
total number of mutations Mutation frequency
PUVA 34/83 41%
UV 36/83 44%
Other 13/83 15%
aMutations arising at 5¢-TpA and 5¢-TpT sites are considered as PUVA type,
whereas C to T, T to C, and CC to TT mutations occurring at dipyrimidine sites
are considered as UV type.
Figure 1. Type and frequency of p53 mutations detected in skin
cancers from PUVA-treated patients. Panel A shows percent of
patients with UVB only, PUVA only, both, or other types of p53
mutation. Panel B shows the frequency and type of base substitutions in
skin tumors from PUVA-treated patients. Mutations arising at 5¢-TpA
and 5¢-TpT sites are considered as PUVA type, whereas C to T, T to C,
and CC to TT mutations occurring at dipyrimidine sites are considered
as UV type; however, it is possible that some of these mutations could
be induced indirectly via oxidative damage caused by PUVA or UVA
alone.
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allele were targets for a second mutational event on the other allele,
or (ii) that these mutations may have arisen independently, perhaps
in different clonal subpopulations during tumor development
(Kanjilal et al, 1993). It is possible that mutant p53 alleles with single
base changes were targets of secondary and tertiary mutational
events, perhaps because of repeated exposure to PUVA therapy or
UVB exposure. Alternatively, secondary or tertiary mutations
could also occur in the same p53 allele or different alleles. A third
possibility is that multiple mutations may arise independently,
perhaps in different clonal subpopulations during continued PUVA
therapy or during tumor development. This possibility is supported
by the ®nding that primary tumor masses often consist of clones of
cells that have different biologic properties such as karyotype,
surface receptors, growth rate, and metastatic ability.
In summary, molecular studies using the p53 gene as a marker for
carcinogen-speci®c mutations performed in this study revealed the
presence of PUVA-type mutations. UVB-type mutations, how-
ever, were observed at an equal frequency or even at a slightly
higher frequency in skin cancers arising in PUVA-treated psoriasis
patients. These ®ndings are consistent with the mutagenic effects of
PUVA being an important mechanism for the induction of SCC in
PUVA-treated patients; however, as in the general population,
where exposure to UVB radiation in sunlight is associated with the
development of NMSC, mutations from UVB, both from UVB
phototherapy and natural sunlight, are likely to be more important
in the development of skin cancer in PUVA-treated patients.
Although PUVA and UVB leaves classic mutational footprints in
many tumors that develop in PUVA-treated patients and certainly
play a part in the development of most SCC in patients exposed to
high doses of PUVA, it is dif®cult to rule out the involvement of
other potentially carcinogenic exposures in the development of
NMSC in PUVA-treated patients.
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